top of page

FDA Wants eSTAR to Be the Only Door for PMAs and IDEs. Two Comment Deadlines Are Coming.

Writer: Lexim AI
Lexim AI
Nov 2
7 min read

On September 18, FDA's device and biologics centers issued a draft guidance that would make the eSTAR electronic template mandatory for original PMAs, several PMA supplement types, and 30-Day Notices. Six weeks later, on October 28, they issued a second draft that would do the same for IDE applications. Together with the 510(k) requirement that took effect on October 1, 2023, and the De Novo requirement that followed on October 1, 2025, the two drafts would put nearly every major premarket submission type on one structured template.

Neither draft sets a start date. Both say FDA intends to allow at least one year after the guidance is finalized before electronic submission becomes mandatory. But the comment windows are short: the PMA draft closes on November 17 (docket FDA-2026-D-9429), and the IDE draft closes on December 28 (docket FDA-2026-D-11188).


Why a guidance document can bind

These are unusual guidances. Section 745A(b) of the FD&C Act, as amended by section 207 of the FDA Reauthorization Act of 2017, requires submissions under listed device provisions, including section 515 for PMAs and section 520(g) for IDEs, to be filed in an electronic format that FDA specifies in guidance, starting on a date it sets in final guidance. Section 745A(b)(3) gives FDA explicit authority to set the standards, the timetable, and the criteria for waivers and exemptions that way. Both drafts therefore say that, once final, provisions that use mandatory words such as must or required will be binding, and will not be subject to the usual good guidance practice limit on guidance that creates enforceable obligations (21 CFR 10.115(d)). Everything else in the documents stays a nonbinding recommendation. For sponsors, the format, timing, and exemption sections deserve the attention normally given to a rule, and they are the sections to aim comments at.


What the drafts would require:

PMAs. Once the guidance is final and an implementation date arrives, a covered PMA submission that does not arrive as an electronic submission would not be considered received unless an exemption applies. The draft covers original PMAs, several PMA supplement types, and 30-Day Notices. It does not cover PMA modules or modular shells. FDA says it intends to run a technical screening of PMA eSTARs within 15 calendar days of receipt, in place of the refuse-to-accept review used today. Under the 510(k) version of this mechanism, a submission is considered withdrawn if a replacement eSTAR is not received within 180 days; The FDA Group's analysis reports that the PMA draft sets that window at 360 days. FDA also notes that the PMA template closely follows SMART, the Submission Memo And Review Template that its own reviewers use internally for certain PMA submissions.

IDEs. The IDE draft says that upon finalization, all IDE applications will be required to be submitted as electronic submissions unless they are exempt, and that an application not submitted that way will not be considered received. For CDRH, the submission must go through FDA's electronic portal. FDA says it intends to review and reach a decision on every IDE electronic submission within 30 days of receipt. Today, sponsors can voluntarily use the PreSTAR version of eSTAR for original IDE applications, supplements, and amendments.


How PMA technical screening works

The draft covers five Designated Application Types: original PMAs, Panel-Track supplements, 180-day supplements, real-time supplements, and 30-day notices and 135-day supplements. For the two types that face refuse-to-accept review today, original PMAs and Panel-Track supplements, FDA does not expect to run RTA on an eSTAR, because a properly completed template should already represent an administratively complete submission. Instead it would run a virus scan and a technical screening.

The screening checks two things. First, that the template's answers accurately describe the device; the draft's example is a submission that says there are no tissue-contacting components when there are. Second, that there is at least one relevant attachment for each attachment-type question, so a Product Description question has a product description behind it. FDA intends to begin screening only where the user fee has been paid.

The mechanics matter for scheduling. Screening is anticipated within 15 calendar days of receipt. A file that fails is placed on hold, the applicant is notified by email with the incomplete items identified, and the response must arrive within 360 days or FDA will treat the submission as withdrawn. A timely response is logged as an amendment, the review clock restarts at day 0, and screening repeats within the first 15 days. Once a file passes, the clock continues. Original PMAs and Panel-Track supplements then go to filing review, which the draft notes occurs within 45 calendar days of receipt under 21 CFR 814.42. Screening is a gate in front of filing review, not a replacement for it.


What the templates ask for

eSTAR separates structured data, captured in fields, dropdowns, and checkboxes, from unstructured data, which is submitted as attachments. The template is highly automated: it includes integrated databases such as FDA product codes and FDA-recognized consensus standards, branches on your answers (indicating that software is used, for example, triggers a prompt for software documentation), and links to the relevant regulations and guidance.

The PMA template's sections track 21 CFR 814.20. Beyond cover letter, applicant information, and prior submissions, it asks for device description, indications for use, market history, a benefits, risks, and mitigation discussion, labeling, and, where applicable, reprocessing, sterility, shelf life, biocompatibility, software and cybersecurity, EMC and electrical safety, and performance testing. It also collects quality management system information under 21 CFR 814.20(b)(4)(v) and Part 820, and plans for approval-ordered post-market studies (excluding 522 studies).

The IDE template tracks 21 CFR Part 812 instead: general clinical information (study type, significant-risk confirmation, and any request for an exception from informed consent under 21 CFR 50.24), product description, intended use, a report of prior investigations under 812.27, the investigational plan under 812.25, informed consent materials, sites and investigators, labeling under 812.5, and manufacturing information. FDA says both templates are built to follow SMART, the Submission Memo And Review Template its reviewers use internally, so the order in which you answer questions is close to the order in which the reviewer will write.

On timing, the IDE draft states FDA's intention to decide every IDE electronic submission within 30 days of receipt, and to give a written determination within 30 days for IDEs involving an exception from informed consent. That matches the existing 30-day IDE review period rather than shortening it.


Why the format change matters more than it sounds

eSTAR is not a cover sheet. It is a structured, dynamic PDF whose questions determine what evidence you present and where it goes. A submission built inside it can be screened quickly and compared against others, and an inaccurate or incomplete answer can stop the file at the door. Teams that moved 510(k)s and De Novo requests into eSTAR learned that content planning has to start from the template, not from a legacy table of contents. PMA and IDE teams, who typically assemble larger, more bespoke document sets over longer timelines, now face the same shift.

FDA has not tied this change to review capacity, and it would be a mistake to read a motive into it. But standardizing intake and screening early is consistent with a center that is managing a smaller review workforce: fewer incomplete files reach reviewers, and less reviewer time goes to finding out what is missing.


Exemptions, waivers, and fallbacks

Both drafts list what would stay outside the requirement. For PMAs, FDA intends to exempt interactive review responses; certain amendments (appeals and requests for supervisory review, substantive summary requests, changes of correspondent, legal entity, or address, amendments after decision such as final labeling, and withdrawal requests); and reports, including annual or periodic reports under 21 CFR 814.84(b) and post-approval study reports. Those items remain subject to any applicable eCopy requirements. For IDEs, the intended exemptions are interactive review responses, appeals, withdrawal requests for applications under review, and IDE reports and related amendments. Expanded access compassionate use requests, emergency use reports, and adverse event reports are already exempt from solely electronic submission under FDA's parent 745A(b) guidance.

FDA says it has not identified circumstances that would justify a waiver and does not intend to grant waiver requests, on the premise that the eSTAR PDF is freely available and every applicant should be able to use it. The one fallback it names is technical: where known issues prevent submission through the CDRH Portal, the submission is mailed to the CDRH Document Control Center. CBER-regulated products use the Electronic Submissions Gateway instead of the CDRH Portal.


What is still open

  • No implementation date. The IDE draft says so directly, and the PMA draft ties its date to a final guidance that does not exist yet.

  • Exemptions. Both drafts identify categories of submissions FDA intends to exempt. The details decide whether your submission types are covered, so read those sections closely.

  • Whether the timelines hold. The 15-day PMA screening and 30-day IDE decision commitments are intentions stated in drafts. How screening interacts with PMA review clocks is a fair question to put to FDA in comments.


What to do now

  1. Decide whether to comment. The PMA draft closes November 17. Useful topics include the transition period, exemptions, supplement coverage, the screening process, and the 360-day withdrawal window. The IDE draft closes December 28.

  2. Try the template on live work. eSTAR for PMAs and PreSTAR for IDEs are voluntary today. Building your next submission in them, even in parallel, surfaces gaps while there is no penalty.

  3. Map your document library to the template's questions. Find content that exists only as narrative and would need to become a structured attachment.

  4. Check your portal readiness. IDE sponsors submitting to CDRH will need to work through the electronic portal; confirm accounts and access now, and confirm the route for CBER-regulated products.

  5. Calendar the dates. November 17, December 28, and the final guidance, which will start the one-year clock.

The larger point: FDA is finishing a multi-year move from documents it reads to structured data it screens. The submission types that arrive last are the ones with the most to rebuild.


Sources: FDA, Electronic Submission Template for Premarket Approval Applications (PMA), draft guidance, September 2026 (docket FDA-2026-D-9429); FDA, Electronic Submission Template for Investigational Device Exemption (IDE) Applications, draft guidance, October 28, 2026 (docket FDA-2026-D-11188; Federal Register notice 2026-21953); The FDA Group Insider, Guidance Breakdown: eSTAR Is Coming for PMAs (October 30, 2026) and Guidance Breakdown: FDA Proposes eSTAR for IDEs (October 2026); Regulatory Affairs News, October 2026; Criterion Edge, FDA Medical Device Updates: Evidence Planning for 2026.

Comments


bottom of page